OrbiMed’s Post

The outlook for #biotech IPOs is increasingly optimistic, including the following prediction shared at LSX World Congress. We have the expertise and the team to lead biotech companies through the entire #IPO journey. Contact Dan Dehner to start the conversation. https://lnkd.in/d6ZB_eF3

Endpoints News reports #biotech deals are on track to surpass 2023 as of Q3, thanks to robust AI-driven partnerships and steady venture funding totaling close to $21B. Q3 also saw 16 IPOs raise $3B—already topping last year’s $2.7B. But to exceed last year’s totals, Q4 will need a typical late-year spike in licensing and M&A activity. AI services alone contributed to 139 service deals this year, while M&A remains cautious with 28 deals worth $15.6B in Q3. Read more: https://lnkd.in/eNAg9sDy #VC #Financing

Life sciences VC Francesco De Rubertis hints at a wave of upcoming IPOs, fueled by increased secondary stock offerings. Keep an eye on this space for a parade of new public biotech firms despite market swings. Remember CG Oncology's standout IPO? More poised to follow. Watch for a season of innovation and smart investing ahead! 🚀 #Biotech #InvestmentTrend #SummerHeat

One of the greatest things about being an individual biotech investor is that you don't have to have insider access or special friends at Venture Capital funds In order to invest in embryonic, very early stage biotech firms. In today's public market, there are many fledgling biotech companies that are years away from having a viable product. There's even a few public companies that don't even have viable products in clinical testing yet. Just a few collection of good molecules and hopeful prayers. If you have a taste for risk and you want to get in on the latest innovations before they're even profitable, check out names that make up the exchange traded fund XBI. You'll save a bundle on fees, enjoy more liquidity and more transparency than investing in a VC fund but the effect will basically be the same. These are very young companies. #Biotech #Biotechnology #Wallstreet

Epoch 10: Beyond the Bucks - How Specialist Investors Fuel Biotech Success Does the quality of investors on the cap table influence the long term success of the company? 👉 Investor quality drives market cap? 👉 Investor quality can revive neg EV biotechs? 👉 M&A likelihood correlated to investor quality? 👉 M&A returns correlated to investor quality? https://lnkd.in/dEkBy2bY

🔥 Biotech is heating up for 2025 🔥 Septerna's $288M IPO shows renewed investor confidence in biotech. With this funding, Septerna is paving the way for much-needed treatment options in areas with limited solutions. This momentum signals strong growth for biotech in the coming year—a positive sign for 2025! #biotechgrowth #2025outlook

The #biotech IPO trickle on #Nasdaq isn't at risk of being a flood anytime soon, but it's a welcome sign of improving capital markets for the sector. I spoke to Labiotech.eu about what it could mean for public and private European companies, and policy developments here in the UK. https://lnkd.in/eJUF3Mm3 #lifesciences #investment #capitalmarkets

MARKET TREND: MONEY MOVES The biotech market has continued to see investment growth so far in 2024. High-profile initial public offerings from industry players like CG Oncology, Arrivent Biopharms and Kyverna experienced double-digit stock price growth after entering the market. 📈 This may be an indicator of what is coming next for biotech: more IPOs, and eventually, a more competitive commercial real estate sector in this industry. 🏢 What do you think of this prediction? At 95 Greene, we’re lab-ready and built for companies to make their next discovery. 🔬🧬 Thor Equities Group | SGA (Boston | New York) | McNamara • Salvia, Structural Engineers | Vanderweil Engineers | Sweet Group LLC | JLL | Blake Goodman | Daniel Spero | John Cahill | Craig Eisenhardt | Robert Ryan | Dan Loughlin #95GreeneSt #NJRealEstate #LifeSciences #IPO #CBRE

‘Next Wave of IPOs’ Will Arrive in Summer, Predicts Biotech-Focused VC Partner Delegates at the LSX World Conference in London seemed to agree on one thing—the biotech IPO window finally re-opened this year. This sentiment has persisted despite the fact that the initial run of public offerings died down by the spring. For Francesco De Rubertis, co-founder and partner of London-based life sciences investment firm Medicxi, the current lull is to be expected. What’s more, he expects “at least a number of IPOs” to arrive as soon as the summer. “In the absence of other external [factors], the natural dynamics of markets should say that now there will be another big number of investors that will become active on the public markets, and that will translate in the next wave of IPOs,” he told Fierce in an interview on the sidelines of the LSX conference. https://lnkd.in/d6ZB_eF3 #aspenalert #biotech #bioprocess

Biotech's Renaissance: A Turning Point 4 factors contributing to the resurgence of biotech IPO activity: 1. Pent-up Demand: The prolonged period of subdued IPO activity created pent-up demand among investors eager to capitalize on promising biotech opportunities. 2. Scientific Breakthroughs: Despite setbacks, the biotech industry continues to achieve significant scientific milestones, bolstering investor optimism and confidence in the sector's long-term potential. 3. Market Dynamics: Favorable market conditions, including lower interest rates and improved investor sentiment towards riskier assets, have created a conducive environment for biotech IPOs. 4. Regulatory Support: Regulatory agencies' continued focus on expediting approvals for innovative therapies has provided a regulatory tailwind for biotech companies, enhancing their market prospects. Visit our website to learn more https://lnkd.in/eEWV6mm5 #BiotechResurgence #InvestorOptimism #MarketDynamics